Tempest Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated November 8, 2022, reports the financial results for Tempest Therapeutics, Inc. for the third fiscal quarter ended September 30, 2022. The filing incorporates by reference a press release titled "Tempest Reports Third Quarter 2022 Financial Results and Provides Corporate Highlights" (Exhibit 99.1).
Key Financial Metrics
The provided text serves as a cover document and does not contain specific numerical data. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity for the reported period. These metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document solely announces the issuance of the quarterly results.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that the information is furnished under Item 2.02 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2022 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the corporate highlights.
- Confirm the status of the company's common stock trading on The Nasdaq Stock Market LLC under the symbol TPST.